growth hormone insensitivity syndrome


Also found in: Acronyms.

growth hormone insensitivity syndrome

Laron dwarfism, pituitary dwarfism II An AR condition characterized by severe growth retardation, delayed bone age, occasionally blue sclerae, and physical manifestations of GH deficiency, due to a defect in the GH receptor
Mentioned in ?
References in periodicals archive ?
Insmed Incorporated (Nasdaq: INSM) announced that it has completed the New Drug Application (NDA) to seek regulatory approval of SomatoKine(R) (Mecasermin rinfabate) for the treatment of growth hormone insensitivity syndrome.
SomatoKine(R) is currently in a pivotal Phase III clinical trial for the treatment of Growth Hormone Insensitivity Syndrome (GHIS).
Insmed's most advanced product, SomatoKine(R), is currently in a pivotal Phase III clinical trial for the treatment of Growth Hormone Insensitivity Syndrome (GHIS).
rhIGF-I/rhIGFBP-3 is currently in a pivotal Phase III clinical trial for the treatment of Growth Hormone Insensitivity Syndrome (GHIS).
Insmed's most advanced product, rhIGF-I/rhIGFBP-3, is currently in a pivotal Phase III clinical trial for the treatment of Growth Hormone Insensitivity Syndrome (GHIS).

Full browser ?